The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

Martin Tolar,John A. Hey,Aidan Power,Susan Abushakra

DOI: https://doi.org/10.3390/ijms25052727

IF: 5.6

2024-02-28

International Journal of Molecular Sciences

Abstract:New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer's disease (AD) and other age-related neurodegenerative disorders. We propose a unifying single toxin theory of brain neurodegeneration that identifies new targets and approaches to the development of disease-modifying treatments. An extensive body of genetic evidence suggests soluble aggregates of beta-amyloid (Aβ) as the primary neurotoxin in the pathogenesis of AD. New insights from fluid biomarkers, imaging, and clinical studies provide further evidence for the decisive impact of toxic Aβ species in the initiation and progression of AD. Understanding the distinct roles of soluble and insoluble amyloid aggregates on AD pathogenesis has been the key missing piece of the Alzheimer's puzzle. Data from clinical trials with anti-amyloid agents and recent advances in the diagnosis of AD demonstrate that the driving insult in biologically defined AD is the neurotoxicity of soluble Aβ aggregates, called oligomers and protofibrils, rather than the relatively inert insoluble mature fibrils and amyloid plaques. Amyloid oligomers appear to be the primary factor causing the synaptic impairment, neuronal stress, spreading of tau pathology, and eventual cell death that lead to the clinical syndrome of AD dementia. All other biochemical effects and neurodegenerative changes in the brain that are observed in AD are a response to or a downstream effect of this initial toxic insult by oligomers. Other neurodegenerative disorders follow a similar pattern of pathogenesis, in which normal brain proteins with important biological functions become trapped in the aging brain due to impaired clearance and then misfold and aggregate into neurotoxic species that exhibit prion-like behavior. These aggregates then spread through the brain and cause disease-specific neurodegeneration. Targeting the inhibition of this initial step in neurodegeneration by blocking the misfolding and aggregation of healthy proteins has the potential to slow or arrest disease progression, and if treatment is administered early in the course of AD and other neurodegenerative disorders, it may delay or prevent the onset of clinical symptoms.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the pathogenesis of Alzheimer's Disease (AD) and other neurodegenerative disorders, especially whether these diseases are caused by a single toxin, and to explore how this theory can guide the development of treatment and prevention methods for these diseases. Specifically, the author proposes a unified "single - toxin" theory, believing that the misfolding and aggregation of normal proteins in the brain is the main cause of neurodegenerative diseases. This theory pays special attention to the soluble aggregates of beta - amyloid (Aβ), especially oligomers and protofibrils, as the main neurotoxins in Alzheimer's disease. The paper points out that as people age, the brain clearance mechanism is impaired, leading to the accumulation and aggregation of Aβ, forming toxic aggregates with prion - like behavior. These aggregates spread in the brain, causing neuronal stress, synaptic damage, tau protein pathological spread and ultimately cell death, resulting in the clinical symptoms of AD. In addition, the paper also discusses that other neurodegenerative diseases follow a similar pattern of pathogenesis, in which normal brain proteins are trapped in the aging brain due to impaired clearance mechanisms, and then misfold and aggregate into toxic species, which in turn lead to specific neurodegenerative changes. Therefore, the core issue of the paper is to explain the pathogenesis of AD and other neurodegenerative diseases by proposing the "single - toxin" theory, and to explore new treatment targets and methods based on this theory, aiming to slow down or stop the disease progression by preventing the misfolding and aggregation of healthy proteins. If intervened early, it may delay or prevent the appearance of clinical symptoms.

The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

Insights into the Neurodegenerative Process of Alzheimer's Disease: a Role for Mononuclear Phagocyte-Associated Inflammation and Neurotoxicity

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets

Alzheimer's disease.

A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

Amyloid, Tau, Pathogen Infection and Antimicrobial Protection in Alzheimer’s Disease –conformist, Nonconformist, and Realistic Prospects for AD Pathogenesis

Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches

PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins

Intracellular amyloid toxicity induces oxytosis/ferroptosis regulated cell death

Development of small molecules for disrupting pathological amyloid aggregation in neurodegenerative diseases

The amyloid hypothesis of Alzheimer's disease at 25 years

The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer's Disease: Role for Natural Antioxidants and Immunotherapeutics

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases

Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.